Coronado Biosciences (CNDO) 3.44 $CNDO
Pre-market Equity Watch on Biotech -- ARIAD Pharma, Array BioPharma, Neurocrine Biosciences, Coronado Biosciences, and Ironwood Pharma
PR Newswire - Tue Apr 07, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
NBIX: 48.38 (-1.49), IRWD: 12.87 (-0.13), CNDO: 3.44 (-0.53), ARIA: 8.27 (-0.15), ARRY: 3.51 (-0.01)
Coronado Biosciences Forms New Subsidiary, DiaVax Biosciences, to Develop Novel Immunotherapies for Cytomegalovirus
GlobeNewswire - Thu Apr 02, 6:30AM CDT
Coronado Biosciences, Inc., (Nasdaq:CNDO) has formed a new subsidiary company, DiaVax Biosciences, to develop novel immunotherapies for the prevention and treatment of cytomegalovirus (CMV), a common virus that affects people of all ages. According to the U.S. Centers for Disease Control and Prevention (CDC), while CMV is typically asymptomatic in healthy individuals, it can cause serious, often life-threatening disease in those with weakened or uneducated immune systems (including developing fetuses exposed to the virus in utero).
CNDO: 3.44 (-0.53)
Coronado Biosciences, Inc. (CNDO) in Focus: Stock Jumps 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 8:18AM CDT
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
CNDO: 3.44 (-0.53), ACOR: 27.07 (-0.45)
Most active Nasdaq-traded stocks
AP - Fri Mar 20, 12:25PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MU: 12.14 (-0.37), FB: 116.62 (-1.94), CNDO: 3.44 (-0.53), AAL: 33.14 (-0.26), CMCSK: 58.00 (-1.69), MSFT: 51.48 (-0.14), INTC: 32.04 (+0.10), CMCSA: 62.80 (-0.13), AAPL: 98.83 (-0.82), CSCO: 29.03 (-0.11)
Coronado Biosciences Announces the Formation of Mustang Therapeutics, Inc. in Partnership With the City of Hope in Duarte, CA
GlobeNewswire - Thu Mar 19, 6:30AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) announced today the formation of a new company, Mustang Therapeutics, Inc. Mustang will initially focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology. This portfolio of CAR-T cells was developed by Dr. Stephen Forman, Director, T cell Therapeutics Research Laboratory and the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, and Dr. Christine Brown, Associate Director, T cell Therapeutics Research Laboratory and Associate Research Professor. The deal is valued in excess of $40 million for the development of these CAR-T cells via up-front and milestone payments to City of Hope. It is anticipated that the first two CAR-T cells from this partnership will begin enrollment in human clinical trials at the City of Hope this year.
CNDO: 3.44 (-0.53)
Coronado Biosciences Announces Exclusive Licensing Agreement With NeuPharma to Develop and Commercialize Novel Covalent 3rd Generation EGFR Inhibitors
GlobeNewswire - Thu Mar 19, 6:00AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) announced today the execution of an exclusive license agreement with NeuPharma, Inc. to develop and commercialize novel irreversible, 3 Generation EGFR inhibitors on a worldwide basis outside of certain Asian countries. The program is currently in pre-clinical development. Under the terms of the agreement, Coronado will pay NeuPharma an up-front licensing fee as well as make development and sales-based milestone payments and will pay a tiered single digit royalty on net sales.
CNDO: 3.44 (-0.53)
Coronado reports 4Q loss
Automated Insights - Mon Mar 16, 6:45AM CDT
BURLINGTON, Mass. (AP) _ Coronado Biosciences Inc. (CNDO) on Monday reported a loss of $3.7 million in its fourth quarter.
CNDO: 3.44 (-0.53)
Pre-market Equity Watch on Biotech -- ARIAD Pharma, Array BioPharma, Neurocrine Biosciences, Coronado Biosciences, and Ironwood Pharma
PR Newswire - Tue Apr 07, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
NBIX: 48.38 (-1.49), IRWD: 12.87 (-0.13), CNDO: 3.44 (-0.53), ARIA: 8.27 (-0.15), ARRY: 3.51 (-0.01)
Coronado Biosciences Forms New Subsidiary, DiaVax Biosciences, to Develop Novel Immunotherapies for Cytomegalovirus
GlobeNewswire - Thu Apr 02, 6:30AM CDT
Coronado Biosciences, Inc., (Nasdaq:CNDO) has formed a new subsidiary company, DiaVax Biosciences, to develop novel immunotherapies for the prevention and treatment of cytomegalovirus (CMV), a common virus that affects people of all ages. According to the U.S. Centers for Disease Control and Prevention (CDC), while CMV is typically asymptomatic in healthy individuals, it can cause serious, often life-threatening disease in those with weakened or uneducated immune systems (including developing fetuses exposed to the virus in utero).
CNDO: 3.44 (-0.53)
Coronado Biosciences, Inc. (CNDO) in Focus: Stock Jumps 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 8:18AM CDT
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
CNDO: 3.44 (-0.53), ACOR: 27.07 (-0.45)
Most active Nasdaq-traded stocks
AP - Fri Mar 20, 12:25PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MU: 12.14 (-0.37), FB: 116.62 (-1.94), CNDO: 3.44 (-0.53), AAL: 33.14 (-0.26), CMCSK: 58.00 (-1.69), MSFT: 51.48 (-0.14), INTC: 32.04 (+0.10), CMCSA: 62.80 (-0.13), AAPL: 98.83 (-0.82), CSCO: 29.03 (-0.11)
Coronado Biosciences Announces the Formation of Mustang Therapeutics, Inc. in Partnership With the City of Hope in Duarte, CA
GlobeNewswire - Thu Mar 19, 6:30AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) announced today the formation of a new company, Mustang Therapeutics, Inc. Mustang will initially focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology. This portfolio of CAR-T cells was developed by Dr. Stephen Forman, Director, T cell Therapeutics Research Laboratory and the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, and Dr. Christine Brown, Associate Director, T cell Therapeutics Research Laboratory and Associate Research Professor. The deal is valued in excess of $40 million for the development of these CAR-T cells via up-front and milestone payments to City of Hope. It is anticipated that the first two CAR-T cells from this partnership will begin enrollment in human clinical trials at the City of Hope this year.
CNDO: 3.44 (-0.53)
Coronado Biosciences Announces Exclusive Licensing Agreement With NeuPharma to Develop and Commercialize Novel Covalent 3rd Generation EGFR Inhibitors
GlobeNewswire - Thu Mar 19, 6:00AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) announced today the execution of an exclusive license agreement with NeuPharma, Inc. to develop and commercialize novel irreversible, 3 Generation EGFR inhibitors on a worldwide basis outside of certain Asian countries. The program is currently in pre-clinical development. Under the terms of the agreement, Coronado will pay NeuPharma an up-front licensing fee as well as make development and sales-based milestone payments and will pay a tiered single digit royalty on net sales.
CNDO: 3.44 (-0.53)
Coronado reports 4Q loss
Automated Insights - Mon Mar 16, 6:45AM CDT
BURLINGTON, Mass. (AP) _ Coronado Biosciences Inc. (CNDO) on Monday reported a loss of $3.7 million in its fourth quarter.
CNDO: 3.44 (-0.53)
